Intervention

TAK-700

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 6 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6
Recruiting0
Common conditions2
Lead sponsors shown4
Advertisement

Clinical trials

6 shown
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone MetastasisNCT01816048 · 2013-05-01
TERMINATED
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerNCT01809691 · 2013-03-08
COMPLETED
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate CancerNCT01546987 · 2012-05-01
COMPLETED
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate CancerNCT01084655 · 2010-07-01
COMPLETED
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific AntigenNCT01046916 · 2010-05-01
COMPLETED
Safety Study of TAK-700 in Subjects With Prostate Cancer.NCT00569153 · 2008-04-01
COMPLETED

Trial status mix

COMPLETED5
TERMINATED1

Phase mix

PHASE24
PHASE12
PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.